AbbVie Inc. (NYSE:ABBV) is one of the 10 undervalued blue chip stocks analysts recommend for smart investing. On June 18, the ...

Drug company shares are down amid President Donald Trump’s assault on the industry, but some in Congress see value.

AbbVie’s stock danced a volatile jig on June 20th, teasing both bulls and bears before landing barely changed at $185.30. The ...

AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

AbbVie ABBV has built a substantial oncology franchise. Initially anchored by blood cancer drugs Imbruvica and Venclexta, the ...

AbbVie Inc. (NYSE:ABBV) is one of the best dividend stocks for a bear market. The company holds the title of a Dividend King, ...

The trial judged the tolerability, safety and efficacy of atogepant, at 60 milligrams once daily, compared to the ...

Antibody drug conjugates, or ADCs, are still holding on to their spot as one of the hottest areas in cancer care—and AbbVie, ...

AbbVie’s migraine drug Atogepant just cleared a major Phase 3 hurdle, and it’s got Wall Street rubbing its temples—in ...

AbbVie said on Wednesday its migraine drug met the main goal and was superior to a widely used generic treatment in a head-to ...

AbbVie's atogepant showed fewer side effects and greater efficacy than topiramate in a Phase 3 migraine prevention trial.